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Abstract The goal of this study was to examine meta-
bolic differences between a novel chronic myelogenous
leukemic (CML) cell line, MyL, and a sub-clone, MyL-R,
which displays enhanced resistance to the targeted Bcr-Abl
tyrosine kinase inhibitor imatinib.
1H nuclear magnetic
resonance (NMR) spectroscopy was carried out on cell
extracts and conditioned media from each cell type. Both
principal component analysis (PCA) and speciﬁc metabo-
lite identiﬁcation and quantiﬁcation were used to examine
metabolic differences between the cell types. MyL cells
showed enhanced glucose removal from the media com-
pared to MyL-R cells with signiﬁcant differences in pro-
duction rates of the glycolytic end-products, lactate and
alanine. Interestingly, the total intracellular creatine pool
(creatine ? phosphocreatine) was signiﬁcantly elevated in
MyL-R compared to MyL cells. We further demonstrated
that the MyL-R cells converted the creatine to phospho-
creatine using non-invasive monitoring of perfused algi-
nate-encapsulated MyL-R and MyL cells by in vivo
31P
NMR spectroscopy and subsequent HPLC analysis of
extracts. Our data demonstrated a clear difference in the
metabolite proﬁles of drug-resistant and sensitive cells,
with the biggest difference being an elevation of creatine
metabolites in the imatinib-resistant MyL-R cells.
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1 Introduction
The presence of the Bcr-Abl fusion protein is a distin-
guishing characteristic of chronic myelogenous leukemia
(CML) (Rowley 1973; Melo et al. 1993). Resulting from
the reciprocal translocation of chromosomes 9 and 22, the
Bcr-Abl protein possesses aberrant and constitutive kinase
activity and is the oncogene responsible for CML devel-
opment and progression (Daley et al. 1990). A major
advance in CML and cancer therapy came with the intro-
duction of imatinib (Gleevec, Novartis), a highly speciﬁc
kinase inhibitor designed to inhibit the tyrosine kinase
activity of the Bcr-Abl protein (Deininger et al. 1997;
Druker et al. 1996). While imatinib has been extremely
successful in the treatment and management of CML for
many patients, the development of imatinib resistance
remains a clinical problem (Apperley 2007).
Many mechanisms have been described and may con-
tribute to imatinib resistance, including increased Bcr-Abl
expression (Mahon et al. 2000; Campbell et al. 2002),
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DOI 10.1007/s11306-010-0204-0multi-drug resistance protein over expression (Kuwazuru
et al. 1990; Illmer et al. 2004), Bcr-Abl-independent
tyrosine kinase signaling (Donato et al. 2003; Ito et al.
2007), and speciﬁc Bcr-Abl point mutations within the
imatinib-binding site (Gorre et al. 2001). Additionally, the
remodeling of cellular metabolism has been explored and
described as a possible mechanism underlying enhanced
cell proliferation and growth in imatinib resistance
(Klawitter et al. 2009). Human CML cell lines with loss of
imatinib sensitivity display increased glycolytic rates, as
evidenced by high lactate production, and elevations in
phosphocholines, metabolic events thought to support
increased cell proliferation in the presence of imatinib
exposure (Kominsky et al. 2009). Additionally, imatinib
treatment has been shown to limit glucose uptake and
metabolism for de novo nucleic acid and fatty acid syn-
thesis through inhibition of the oxidative branch of the
pentose phosphate shunt (Boren et al. 2001). Within the
context of imatinib resistance, a shift from the oxidative to
the non-oxidative, transketolase dependent pathway may
overcome imatinib’s inhibitory effects and thereby support
the sufﬁcient generation of important macromolecules for
continued cell proliferation (Boros et al. 2003).
With the development of high resolution nuclear mag-
netic resonance (NMR) spectroscopy, the identiﬁcation and
quantiﬁcation of cellular metabolites, second messengers,
lipids, and other small molecules within biological systems
are possible (Grifﬁn 2003). When coupled to multivariate
statistical analysis methods, such as principal component
analysis (PCA), processed spectral data from various bio-
logical conditions can be distinguished from each other
based upon differences within their unique metabolic pro-
ﬁles in an unbiased manner (Reo 2002). Furthermore, use
of NMR spectroscopy allows for quantiﬁcation of indi-
vidual metabolites (Weljie et al. 2006). These data can lead
to potential ‘‘biomarker’’ identiﬁcation and provide a better
understanding of the possible role cellular metabolism
contributes to a particular disease state, drug response, or
alteration in biological condition.
Here we examined and compared the metabolic proﬁles
of a recently isolated and characterized CML cell line and a
subline, which displays resistance to imatinib using
1H
NMR. Our data show that when maintained in imatinib-
free culture conditions, cells previously made resistant to
imatinib-mediated cell death, maintained this resistance
and displayed a unique metabolic phenotype compared to
the parental CML cell line. The resistant cells showed
suppressed glycolysis, lower overall levels of choline
derivatives, lower taurine levels and elevated creatine. We
further demonstrated that the resistant cells maintained a
portion of the creatine pool as phosphocreatine, which may
provide an additional energy reserve allowing cells to
escape imatinib-mediated cell death.
2 Materials and methods
2.1 Materials
NMR supplies were obtained from multiple vendors.
Sodium alginate, calcium chloride, perchloric acid, sodium
citrate, sodium chloride, potassium chloride, and 3-(trim-
ethylsily) propionic-2,2,3,3-d4 acid (TSP) were purchased
from Sigma Chemical company (St. Louis, MO). Mono
and dibasic phosphate was purchased from Mallinckrodt
(Paris, KY). RPMI (Gibco) and fetal bovine serum were
purchased from Invitrogen (Carlsbad, CA). Deuterium
oxide was from Cambridge Isotope Laboratories (Andover,
MA). The 5 and 10 mm NMR tubes were purchased from
Wilmad Labglass Inc. (Miamisburg, OH). Materials for the
bioreactor and life support system can be found in Keshari
et al. (2010) and others (R. Jeffries et al., unpublished).
2.2 Cell culture
The human CML cell line, MyL, and the imatinib-insen-
sitive subline, MyL-R, were kindly provided by Dr. Hideo
Tanaka (Department of Haematology and Oncology,
Hiroshima University, Hiroshima, Japan). Each cell type
was maintained at 37C with 95% air and 5% CO2 in RPMI
medium (GIBCO) with 10% fetal bovine serum (FBS) and
antibiotic/antimycotic (Cellgro) and were determined to be
mycoplasma free. As originally reported, MyL-R cells
could be maintained in imatinib-free culture medium for up
to 6 months without an alteration in their sensitivity to
imatinib.
For the comparison of MyL and MyL-R by
1HN M R ,
1 9 10
8 cells were incubated for 2 h in 20 ml of fresh
RPMI medium (RPMI ? 10% FBS). Following the incu-
bation, the cells were collected by centrifugation, washed
39 with cold PBS and then extracted with cold-methanol
method as described below. Approximately 1 ml of the
conditioned media from each cell type was collected for
1H
NMR analysis.
2.3 Cold methanol cell extraction
Cells were harvested by low-speed centrifugation and
metabolites extracted using the cold methanol extraction as
previously described (Maharjan and Ferenci 2003). Brieﬂy,
the cells were collected by centrifugation and washed three
times with cold PBS. Following removal of the last wash,
500 ll of ice-cold 50% methanol was added to the cell
pellet and vortexed. The cell extracts were then incubated
for 30 min on dry ice, and then allowed to thaw for 10 min
on ice. The extracts were clariﬁed by centrifugation at
16,000g for 10 min. The methanol extract (supernatant)
was collected and transferred to a new microfuge tube,
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123while an additional 500 ll of 50% methanol was added to
the pellet for a second extraction. The second 50% meth-
anol extract was collected and combined with the previous
(ﬁrst) extract. The total cell extract was evaporated to
dryness using a Speed-Vac
.
2.4 Sample preparation and NMR spectroscopy
Prior to NMR spectroscopy, the evaporated cell extract
pellet was suspended in 600 llD 2O containing 1.5 mM
(ﬁnal concentration) TSP and transferred to a 5 mm NMR
tube for subsequent high resolution NMR analysis. For
media analysis, a 400 ll aliquot of conditioned media was
mixed with 200 llo fD 2O containing 4.5 mM TSP. 1D
1H
NMR spectra were acquired on a 16.4T Varian INOVA
(700 MHz
1H, Varian Instruments) equipped with 5 mm
indirect cold probe. The FIDs were acquired using a one-
pulse sequence with a total repetition time (TR) of 12.65 s,
number of transients (nt) of 64 and a 90 ﬂip angle.
2.5 Spectral processing, PCA and metabolite
determination
2.5.1 Spectral processing
All NMR spectra were processed using ACD/1D NMR
Manager (version 12.0; Advanced Chemistry Develop-
ment, Inc., Toronto, ON, Canada). Imported FID’s were
zero ﬁlled to 64,000 points and an exponential line
broadening of 0.1 Hz was applied prior to Fourier trans-
formation. Spectra were phase and baseline corrected, and
referenced to the TSP peak at 0.00 ppm. For in vivo
31P
NMR spectra, the FIDs we zero ﬁlled to 32,000 and an
exponential line broadening of 20 Hz was applied prior to
Fourier transformation.
2.5.2 PCA
Following annotation (removal of spectral regions around
water, [9.7 ppm, \0.4 ppm), grouped spectra were data-
reduced to 250 regions, or bins, using intelligent bucketing
and the integrals within each bin were determined. PCA
was carried out using SIMCA-P (version 11.0; Umetrics,
Umea, Sweden).
2.5.3 Metabolite determination
Metabolite identiﬁcation and quantiﬁcation were deter-
mined using Chenomx NMR Suite (version 5.1; Chenomx
Inc., Edmonton, Canada), using TSP as a concentration
reference.
2.6 In vivo
31P NMR spectroscopy of alginate
encapsulated MyL and MyL-R cells
In vivo
31P NMR spectroscopy was performed using a
ﬂuidized-bed NMR-compatible bioreactor as described
previously (Keshari et al. 2010; R. Jeffries et al.,
unpublished). Brieﬂy, MyL and MyL-R cells were col-
lected by centrifugation, mixed with 1:1 (vol:vol) of 2%
alginate and electrostatically encapsulated and separately
perfused in the bioreactor. The
31P NMR were obtained
on a 14.1 T Varian INOVA (242 MHz
1H, Varian
Instruments) equipped with a 10 mm broadband probe at
37C. The
31P NMR time courses were acquired using a
TR = 2s, nt = 2048 and a 77 ﬂip angle, resulting in
spectra of 68 min each.
2.7 HPLC analysis
To avoid phosphocreatine hydrolysis during extraction,
cells were extracted using perchloric acid. Brieﬂy,
10 9 10
6 cells were collected by centrifugation, washed
three times with cold PBS and then extracted with 500 ll
of 0.6 M HClO4 with 1.0 mM EDTA. After vortex,
extracts were centrifuged for 5 min at 14,000 rpm and then
the supernatant collected. Approximately 80 llo f2 M
KHCO3 was added, followed by a 20-min incubation on
ice, and then a 5-min centrifugation at 12,000 rpm. The
supernatants were collected and stored at -80C. Extracts
were analyzed by HPLC using a reverse phase C-18 col-
umn. Creatine and phosphocreatine standards were used to
determine elution times.
2.8 Cell viability assays
For imatinib dose response experiments, 10 9 10
3 MyL or
MyL-R cells were plated per well in 50 ll of medium in a
96-well plate. An additional 50 ll volume of medium was
added with increasing concentrations of imatinib (DMSO
was used as the vehicle control). After 48 h, 20 ll of MTS
reagent (CellTiter 96
AQueous One Solution Reagent,
Promega, Madison, WI) was added to each well and
incubated for an additional 2 h according to the manufac-
turer’s instructions. The formation of the soluble formazon
product was determined by measuring the absorbance at
490 nm on a SpectraMAX plate reader (Molecular Devi-
ces, Sunnyvale, CA) and subtracting a media ? MTS only
control. Percent viability was calculated from the DMSO
control. Duplicate readings were obtained for each condi-
tion and each experiment was performed three times.
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1232.9 Statistics
Concentrations from cell extracts and media were analyzed
using Prism (GraphPad Software, La Jolla, CA) and sta-
tistical comparisons were made using two-tailed Student’s t
test or analysis of variance (ANOVA), and post hoc com-
parisons were made in pair-wise fashion using Tukey’s
method as appropriate. A value of P\0.05 was selected
before the study as the level of signiﬁcance.
3 Results
3.1 Imatinib resistant MyL-R cells display persistent
resistance to imatinib
Imatinib-resistant cell lines have been generated from
imatinib-sensitive CML cells by maintaining cells in sub-
optimal concentrations of imatinib and gradually increas-
ing the dose over time (Mahon et al. 2000). Recently, a
similar strategy was employed to generate the MyL-R cell
line from the parental CML isolate, MyL. Imatinib resis-
tance in the MyL-R cells was shown not to be a result of
Bcr-Abl over-expression or Bcr-Abl kinase-domain point
mutations. Importantly, the insensitivity to imatinib per-
sisted even when maintained in the absence of imatinib (Ito
et al. 2007). We veriﬁed this persistent insensitivity to
imatinib by maintaining MyL and MyL-R cells in RPMI
medium ? 10% FBS only and then examining the
effectiveness of increasing concentrations of imatinib on
cell viability. As expected, the MyL-R cells showed
enhanced tolerance to imatinib treatment when compared
to MyL cells, even after having been maintained in
imatinib-free culture medium (Fig. 1). These results sug-
gest that the mechanisms associated with resistance are
maintained even when cells are cultured in the absence of
imatinib. Interestingly, MyL-R cells are also highly resis-
tant to gemcitabine, AraC and Immucillin H treatment,
demonstrating an overall increase in MyL-R cell survival
(E. Zimmerman et al., unpublished observations).
3.2 Metabolic phenotype associated with MyL and
MyL-R cells as examined by
1HN M R
We examined the soluble metabolite proﬁles of MyL and
MyL-R cells maintained under the conditions described
above by
1H NMR analysis of both cell extracts and cell-
conditioned media. A representative
1H NMR spectra
(primarily the aliphatic region) of a cell extract from MyL
or MyL-R cells is shown in Fig. 2. By applying PCA to the
NMR spectra generated from MyL and MyL-R cells, met-
abolic differences associated with each cell type were
investigated. The scores plot revealed a separation of MyL
from MyL-R in the ﬁrst principal component (PC1)
(Fig. 3a). The corresponding loadings plot is shown in
Fig. 3b and identiﬁes spectral regions responsible for the
separation observed in the scores plot. The metabolites most
likely associated with these spectral regions are shown.
Fig. 1 Sensitivity of MyL and
MyL-R cells to imatinib
treatment. MyL or MyL-R cells
(10 9 10
3) in 100 ll of medium
were incubated for 48 h with
DMSO (vehicle control) or the
concentrations of imatinib
shown (lM). Percent viability
was determined as described in
Materials and methods (n = 3)
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123From the 1D spectra of cell extracts a total of 56
metabolites were identiﬁed and quantiﬁed using Chenomx
software, based upon the known concentration of TSP
standard added to each sample. A comparison of selected
metabolites from the cell extracts of MyL and MyL-R cells
is shown in Fig. 4a. We observed a statistically signiﬁcant
decrease in several metabolites in MyL-R cells compared
to MyL cells including alanine, glutamine, lysine, choline,
phosphocholine, myo-inositol, AXP, lactate, acetate, acet-
ylaspartate, formate, fumarate, pyroglutamate, succinate,
and taurine. Interestingly, the only metabolite found to be
elevated in MyL-R cells compared to MyL cells was cre-
atine. This was most evident when the MyL-R to MyL ratio
of each metabolite in the cell extracts was determined
(Fig. 4b). Many metabolites, mostly amino acids, showed
little difference between the two cell lines, as shown by a
MyL-R/MyL ratio close to 1.0 and included isoleucine,
leucine, methionine, tyrosine, valine and glutathione.
Similar to cell extracts,
1H NMR spectra were acquired
from Total Medium (RPMI ? 10% FBS only) and MyL
and MyL-R cell-conditioned medium. Table 1 shows the
lmol quantity of selected metabolites from each media
condition. Signiﬁcant differences comparing each cell-
conditioned media to the Total Medium were observed for
the following metabolites: arginine, glucose, glutamine,
histidine, isoleucine, leucine, phenylalanine, proline,
pyroglutamate, fructose and lactate. We observed a sig-
niﬁcant difference in glucose consumption (removal from
the media) where MyL cells consumed 475.36 ± 19.71
nmol/h/10
6 glucose compared to only 297.13 ± 37.81
nmols/h/10
6 in the MyL-R cells. This was accompanied by
a signiﬁcant difference in lactate release, where MyL cells
produced 176.77 ± 9.55 nmols/h/10
6 cells compared to
only 93.44 ± 10.61 nmols/h/10
6 MyL-R cells. We further
observed a signiﬁcant decrease in glutamine and phenyl-
alanine removal from the media by the MyL-R cells. MyL
cell acetate and formate production, 3.25 ± 0.66 and
15.68 ± 3.99 nmol/h/10
6 cells, respectively, were statisti-
cally different and elevated compared to MyL-R formate
production. Interestingly, MyL cells showed a release
or production of alanine into the media compared to the
MyL-R cell, which displayed overall consumption of this
metabolite. Lastly, glutamate release into the media was
elevated in the MyL-R cells compared to the MyL cells,
however this difference was not statistically signiﬁcant
(Table 1).
Fig. 2
1H NMR spectra from
MyL and MyL-R cells extracts.
MyL (a) and MyL-R (b) cells
were expanded and maintained
in T175 ﬂasks containing RPMI
culture medium with 10% FBS
in the absence of imatinib. The
expanded cells were collected
by low speed centrifugation,
counted and then plated at a
density 5.0 9 10
6 cells/ml in
20 ml of fresh medium. After
incubation for 2 h at 37C, the
cells were collected, washed
three times with cold PBS, and
extracted as described in Sect. 2.
Cell extracts were evaporated to
dryness followed by suspension
in D2O containing TSP (internal
standard), and analyzed by
1H
NMR. Spectra are
representative for each cell type
and highlight major metabolites
identiﬁed. Lac lactate, m-Ins
myo-inositol, Gly glycine, Glm
glutamine, PCho
phosphocholine, Cho choline,
Cr creatine, GSH glutathione,
Suc succinate, Pro proline, Ace
acetate, Ala alanine, Val valine,
Ileu isoleucine, Leu leucine,
NAA n-acetylaspartate
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1233.3 MyL-R cells maintain creatine as the high energy
phosphagen, phosphocreatine
Interestingly, one of the most signiﬁcant differences
observed between MyL and MyL-R cells was the total
intracellular creatine pool, which was 5-fold higher in the
MyL-R cells.Fromthe
1HNMRdatawedeterminedthatthe
total intracellular creatine pool (creatine ? phosphocrea-
tine) was 0.601 ± 0.078 nmol/10
6 cells in the MyL as
compared to 2.93 ± 0.43 nmol/10
6 in the MyL-R (Fig. 4a).
Creatine kinase (CK) catalyzes both the forwardand reverse
reaction conversion of creatine to the high-energy phos-
phagen, phosphocreatine utilizing or generating ATP (Wyss
and Kaddurah-Daouk 2000). Because the
1H NMR peaks of
creatine and phosphocreatine are nearly identical, it is dif-
ﬁculttodistinguishbetweencreatineandphosphocreatineby
thismethod. Wethereforegeneratedperchloricacidextracts
ofMyLandMyL-Rcellsandanalyzedthembyreversephase
HPLC(C18)asdescribedinSect.2.Weobservedanincrease
in the total intracellular creatine pool (creatine ? phospho-
creatine) in MyL-R compared to MyL cells and the values
determined from HPLC in nmols/10
6 cells were comparable
to those obtained by
1H NMR (Fig. 5a). Interestingly, MyL-
R cells maintained a creatine/phosphocreatine ratio close to
1.0, whereas in the MyL cells more of the total intracellular
creatine pool was in the form of creatine (Fig. 5b).
We further conﬁrmed the ability of the MyL-R cells to
convertcreatinetophosphocreatineusingarecentlydesigned
Fig. 3 Metabolic distinction of MyL from MyL-R cells. a Scores plot
(PC1/PC2) based on
1H NMR spectra of cell extracts from MyL and
MyL-R cells grown in the absence of imatinib. b Corresponding
loadings plot. Values given correspond to chemical shift values (ppm)
from
1H spectra (n = 8)
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123NMR-compatible bioreactor. Alginate encapsulated MyL-R
cells were loaded into the lower chamber of the bioreactor
NMRtubeandinvivo
31PNMRspectrawereacquiredevery
30 min over an 8-h time period. We observed a clear peak
representingphosphocreatineduringtheentiredurationofthe
experiment(Fig. 5c)conﬁrmingthatunderinvivoconditions
MyL-R cells maintain a portion of their intracellular creatine
pool in the form of phosphocreatine. Inset in Fig. 5c is the
comparison of the in vivo
31P NMR spectra from MyL and
MyL-Rcellsperfusedinthebioreactordemonstratingthatthe
primary difference between the two spectra is the greatly
reduced phosphocreatine peak in the MyL cells.
4 Discussion
We used
1H NMR based metabolomic analysis to compare
MyL, a Bcr-Abl
? human CML cell line, to a subline that
Fig. 4 Quantiﬁcation of the
intracellular metabolites in MyL
and MyL-R cells. a Individual
metabolite concentrations from
1H NMR processed spectra were
determined using Chenomx
software and calculated as
nmol/10
6 cells. * P\0.05 for
comparison between MyL and
MyL-R by two-tailed student’s t
test (n = 8). b MyL-R to MyL
ratio for each metabolite shown
in (a)
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123displays resistance to imatinib. By comparing the overall
metabolic proﬁles of these cells we hoped to determine if
imatinib resistant cells displayed a unique metabolic sig-
nature different from the non-resistant cell line. Previous
work has demonstrated that Bcr-Abl expression results in
elevated cellular levels of Glut-1 protein and imatinib
treatment resulted in decreased glucose uptake due to Glut-
1 internalization (Barnes et al. 2005). Interestingly, more
recent evidence has shown that Glut-1 internalization did
not occur when imatinib resistant cell lines were cultured in
the presence of imatinib and thus, glucose uptake and
metabolism is maintained (Kominsky et al. 2009). Here our
data demonstrate that when maintained in culture in the
absence of imatinib, the MyL-R cells display a different
glycolytic proﬁle when compared to both the imatinib
sensitive MyL cells and previously reported data. We
observed lower glucose removal from the media by MyL-R
in comparison to the MyL cells and both the intracellular
lactate concentration and release into the culture medium
was lower in MyL-R cells compared to MyL (Fig. 4a,
Table 1). If for every mole of glucose metabolized by
glycolysis two moles of lactate are produced, then the
percent of glucose used for glycolysis for MyL and MyL-R
cells is 36 and 18%, respectively. The two major metabolic
pathways that utilize glucose in transformed cells are the
pentose phosphate pathway for generation of ribose in
RNA and DNA synthesis, and pyruvate entry into mito-
chondrial TCA cycle. Signiﬁcant alterations in diversion of
glucose into the pentose phosphate pathway have been
described in response to imatinib treatment (Boren et al.
2001). Future experiments employing
13C-labeled glucose
could be done to determine relative glucose ﬂux into these
other pathways and to more accurately deﬁne the differ-
ence in percent glucose generated lactate between MyL and
MyL-R cells.
Recent evidence has demonstrated the importance of
glutamine in cancer cells undergoing high rates of aerobic
glycolysis (DeBerardinis et al. 2007). Due to a high efﬂux
rate of substrates of the TCA cycle, particularly citrate,
which is used for fatty acid synthesis, glutamine anapleu-
rosis replenishes TCA substrates through conversion of
glutamine to a-ketoglutarate (DeBerardinis et al. 2007). In
Table 1 Change in selected metabolites from Total Medium following incubation with MyL and MyL-R cells
Metabolite Total medium
(lmols)
Conditioned (lmols) Consumption or production (nmols/h/10
6 cells)
MYL MYL-R MyL MyL-R
Arginine 17.60 ± 0.55 12.84 ± 0.24
a 12.99 ± 1.61 23.62 ± 1.31 21.12 ± 8.05
Aspartate 3.42 ± 0.38 2.02 ± 0.22 2.51 ± 0.30 7.59 ± 1.19 4.53 ± 1.50
Choline 0.62 ± 0.04 0.39 ± 0.04 0.45 ± 0.06 1.21 ± 0.18 0.83 ± 0.29
Glucose 201.33 ± 6.19 113.29 ± 3.66
a 141.81 ± 7.56
a 475.36 ± 19.71 297.13 ± 37.81
b
Glutamate 3.51 ± 0.14 3.43 – 0.22 4.82 – 0.99 0.44 ± 1.20 6.55 – 4.69
Glutamine 24.34 ± 0.61 15.63 ± 0.60
a 20.07 ± 0.42
a 34.21 ± 3.22 9.44 ± 2.10
b
Glycine 3.87 ± 0.09 4.80 – 0.86 4.06 – .75 6.00 – 4.64 1.81 – 3.73
Histidine 2.03 ± 0.07 1.37 ± 0.07
a 1.71 ± 0.27 3.59 ± 0.36 1.61 ± 1.33
Isoleucine 7.21 ± 0.74 4.34 ± 0.21
a 4.53 ± 0.55
a 16.44 ± 1.13 14.24 ± 2.77
Leucine 7.06 ± 0.59 3.88 ± 0.07
a 4.47 ± 0.59
a 17.69 ± 0.40 13.44 ± 3.00
Phenylalanine 2.03 ± 0.14 1.17 ± 0.02
a 1.49 ± 0.11 4.68 ± 0.13 2.74 ± 0.54
b
Proline 4.00 ± 0.19 2.26 ± 0.07
a 2.99 ± 0.58 9.23 ± 0.40 5.16 ± 2.90
Pyroglutamate 9.03 ± 0.67 2.64 ± 0.12
a 2.92 ± 0.16
a 38.43 ± 0.63 34.18 ± 0.81
Valine 3.77 ± 0.06 2.57 ± 0.25 2.48 ± 0.35 6.54 ± 1.33 6.49 ± 1.75
Acetate 0.41 ± 0.05 1.01 – 0.12 0.69 – 0.20 3.25 – 0.66 1.42 – 1.00
b
Alanine 2.06 ± 0.09 3.05 – 0.22 1.52 ± 0.29 5.32 – 1.21 2.70 ± 1.44
b
Formate 0.69 ± 0.02 3.59 – 0.74 2.68 – 0.73 15.68 – 3.99 9.95 – 3.66
b
Fructose 6.96 ± 0.57 4.33 ± 0.09
a 5.31 ± 0.95 14.23 ± 0.47 8.27 ± 4.77
Lactate 33.70 ± 0.46 68.24 – 1.76
a 54.23 – 2.12
a 176.77 – 9.55 93.44 – 10.61
b
Total medium (RPMI ? 10% FBS) or medium incubated with either MyL or MyL-R cells for 2 h were analyzed by
1H NMR. Individual
metabolites were identiﬁed and quantiﬁed using Chenomx software as described in Sect. 2. The relative consumption or production rates were
calculated by subtracting each cell condition from the mean Total Medium value and dividing by incubation time and total number of cells.
Results are expressed as mean ± SEM, n = 3. Values in Bold represent metabolites that accumulated (production) in medium
a p\0.05 for comparison with Total Medium by ANOVA with post hoc test using Tukey’s method
b p\0.05 for comparison between MyL and MyL-R by Student’s t test
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123this study MyL cells, which displayed higher rates of
glycolysis also consumed more glutamine from the culture
media compared to the MyL-R cells (Table 1). Moreover,
we observed an accumulation of glutamate in the MyL-R
media. As glutamine must ﬁrst be converted to glutamate,
and then subsequently to a-ketoglutarate for entry into the
TCA cycle, the diminished role of glutamine anapleurosis
in the MyL-R cells may be reﬂected by an accumulation of
glutamate. These data suggest that mitochondrial metabo-
lism in the MyL-R cells may be in an alternative metabolic/
respiratory state when compared to the highly glycolytic
MyL cells. Indeed, succinate and adenosine phosphates
(AXP) levels were signiﬁcantly lower in MyL-R cells
extracts, with the later being possibly related to the ele-
vations observed in the creatine/phosphocreatine ratio
(Fig. 4). This altered mitochondrial state may simply be due
tothereductioninglycolyticﬂuxobservedintheMyL-Rcells.
However, a recent study demonstrated that glutamine-
dependent anapleurosis regulated MondoA, a nutrient-
dependenttranscriptionfactor,whichconsequentlycontrolled
Fig. 5 In vivo detection of
phosphocreatine in MyL-R
cells. Perchloric acid extracts
from 10 9 10
6 MyL and
MyL-R cells from normal
growth conditions were
analyzed by HPLC to determine
intracellular creatine (Cr) and
phosphocreatine (PCr)
concentrations (a) and the
Cr/PCr ratio (b). Stacked
31P
spectra of viable MyL-R cells in
an NMR compatible bioreactor
(c). Inset in (c) is the
comparison of
31P spectra from
perfused alginate-encapsulate
MyL and MyL-R cells
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123glucose uptake (Kaadige et al. 2009). Whether these
mitochondrial alterations in metabolism are critical to drug
resistance remain to be elucidated.
Choline and metabolic pathways associated with choline
metabolism are often elevated in cancerous tissues (Ac-
kerstaff et al. 2003). Moreover, previous work has dem-
onstrated an overall increase in phosphocholine (PC) and
glycerophosphocholine (GPC) in chronic lymphocytic
leukemia cells compared to normal human lymphocytes
(Franks et al. 2002). More recent evidence has demon-
strated that the ratio of PC/GPC can be used as a measure
of enhanced cell proliferation in cancerous tissues (Glunde
et al. 2006). A signiﬁcant rise in PC and loss of GPC was
observed in imatinib resistant CML cell when compared to
their sensitive counterparts (Serkova and Boros 2005). In
this study, comparing drug sensitive to resistant cells we
observed an overall decrease in choline and choline
derivatives (PC and GPC) in the imatinib resistant MyL-R
cell compared the MyL line (Fig. 4a). These data suggest
the possibility that the proliferation rate of MyL-R cells
differs and may be slightly slower than that of the MyL
cells. However, it should be noted that while the overall PC
and GPC levels were lower in the MyL-R cell presented
here, there was only a slight increase in the PC/GPC ratio
compared to the MyL cells. Compared to previous reports
demonstrating a signiﬁcant change in the PC/GPC ratio in
resistant cell, the modest increase in the PC/GPC ratio
observed here in imatinib resistance cells could be due to
the absence of imatinib in their growth media, a selective
pressure promoting enhanced cell proliferation to over-
come the cytostatic effects of the drug.
Taurine is a conditionally essential amino acid, not
utilized for protein synthesis but found free in the cyto-
plasm or in short peptides. The biological importance and
physiological functions of cellular taurine are numerous
and highly cell type speciﬁc (Huxtable 1992). We observed
taurine in both MyL and MyL-R cell extracts, however
intracellular concentrations were signiﬁcantly lower in the
MyL-R imatinib resistant subline (Fig. 4a). Other work has
observed similar differences in vinblastine-sensitive and
resistant T-lymphoid leukaemic cell lines where taurine
was signiﬁcantly lower in the resistant cell line (Jiang et al.
1993). A more recent report provides evidence that
increased taurine levels correlated with apoptosis in glioma
cells (Opstad et al. 2009), however, in contrast, taurine can
act as a cellular anti-oxidant and has been shown to protect
against high-glucose induced apoptosis in vascular endo-
thelial cells (Wu et al. 1999).
From our data and analysis of cell extracts the elevation
of the total creatine pool in the MyL-R cells was the most
distinguishing feature comparing this drug resistant cell
model from the parental non-resistant cells (Fig. 4b). A rise
in the high-energy compound phosphocreatine and its
precursor, creatine, has been observed in drug resistant
human breast cancer cells (Kaplan et al. 1990). The
mechanism for the elevation of total intracellular creatine
in the imatinib-resistant cells is unknown, however other
works have demonstrated that increased intracellular levels
of creatine are associated with cell differentiation and were
due to enhanced uptake (Loike et al. 1984, 1986). Alter-
natively, de novo creatine synthesis could be accounting
for the elevated levels. However, the primary tissues
involved and expressing key enzymes required for creatine
synthesis are kidney and liver, thus making de novo syn-
thesis in leukemic cells unlikely.
The signiﬁcance of the elevated creatine in the MyL-R
cells and its possible role in imatinib-resistance is not
known at this time. However, modulation of the mito-
chondrial permeability transition and cytochrome c release
leading to apoptotic induction, an event thought to be
induced by imatinib treatment, has been shown to be
affected by mitochondrial phosphocreatine levels (O’Gor-
man et al. 1997; Dolder et al. 2003). Imatinib treatment has
been shown to decrease glycolysis, an ATP generating
process (Boren et al. 2001; Gottschalk et al. 2004) and
moreover, prolonged imatinib treatment has been shown to
deplete phosphocreatine in K562 cells (Klawitter et al.
2009). Thus cells possessing an alternative high-energy
source may ultimately stave off loss of cell viability better
than ones lacking or contain less of that alternative energy
supply.
This work further suggests that metabolic differences
may exist between parental CML cell line models. As
mentioned above, the presence of phosphocreatine has
been reported in the K562 cell line, a commonly described
imatinib sensitive CML cell line model (Gottschalk et al.
2004). Here, only low levels of phosphocreatine were
observed in the parental MyL cell line. This difference
could be due to lineage speciﬁc cell differences as K562
represent have an erythrocytic lineage, whereas the MyL
line has been described as more monocytic. Additionally,
K562 represent a late stage blast crisis CML, while the
MyL cell line model may better represent an earlier stage
of CML.
5 Concluding remarks
In this study we performed a metabolic comparison of a
recently characterized CML cell line, MyL, and its imatinib
resistant counterpart, MyL-R. The original work describing
this novel cell line model demonstrated that as opposed to
other human CML cell lines displaying imatinib resistance,
the MyL-R cells show no Bcr-Abl kinase domain muta-
tions, lack elevated Bcr-Abl expression, and did not
express multi-drug transport channels. Using NMR based
448 B. J. Dewar et al.
123metabolomic analysis, we observed that the imatinib
resistant CML cell line displayed a noticeably different
metabolite proﬁle compared to the drug sensitive parental
cell line. Most notable were signiﬁcantly higher creatine
and phosphocreatine levels and an overall decrease in
glycolytically related endpoints. Thus, similar to previous
works, our data support the idea that CML cells undergoing
high rates of glycolytic metabolism (i.e. the Warburg
effect) in order to support high rates of cellular prolifera-
tion tend to be more sensitive to imatinib treatment. In this
study however, our data suggest that the inherent metabolic
differences, that the MyL-R cells are less dependent upon
glycolytic metabolism and have a possible alternative
energy store in the form of phosphocreatine, may make the
MyL-R cells less susceptible to imatinib treatment and
therefore contribute to their drug resistance. Further works
will be required to examine the relevance of these meta-
bolic differences in relation to imatinib drug resistant.
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